Associations of non-alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: A Mendelian randomization study

被引:3
|
作者
Deng, Yunyang [1 ]
Huang, Junjie [1 ]
Wong, Martin Chi Sang [1 ,2 ,3 ,4 ]
机构
[1] Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Sch Publ Hlth, Beijing, Peoples R China
[3] Peking Univ, Sch Publ Hlth, Beijing, Peoples R China
[4] Chinese Univ Hong Kong, Fac Med, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong 999077, Peoples R China
关键词
cirrhosis; hepatocellular carcinoma; liver cancer; Mendelian randomization; non-alcoholic fatty liver disease; EPIDEMIOLOGY; RISK;
D O I
10.1002/cnr2.1913
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background :The positive relationships of non-alcoholic fatty liver disease (NAFLD) and cirrhosis with liver cancer were shown in previous observational studies, while further Mendelian randomization (MR) investigations are needed to confirm the possible causal associations.Aims :This study aimed to explore whether NAFLD and cirrhosis were causally related to liver cancer using MR in European and East Asian populations.Methods and Results :For European populations, NAFLD data were obtained from a genome-wide meta-analysis (8434 patients and 770 180 controls). The data on chronic elevation of alanine aminotransferase (cALT), a proxy of NAFLD, were derived from Million Veteran Program (68 725 patients and 95 472 controls). Cirrhosis data were collected from two sources: a genome-wide association study of five cohorts (4829 patients and 72 705 controls) and FinnGen (1931 patients and 216 861 controls). Liver cancer data were collected from FinnGen (304 patients and 174 006 controls). For East Asian populations, the data on cirrhosis (2184 patients and 210 269 controls) and hepatocellular carcinoma (1866 patients and 195 745 controls) were obtained from Biobank Japan. Three, 41, seven, six, and three single-nucleotide polymorphisms were used for NAFLD (European), cALT (European), cirrhosis (European-five cohorts), cirrhosis (European-FinnGen), and cirrhosis (East Asian), respectively. We used inverse-variance weighted as the primary method to calculate the odds ratio (OR) and 95% confidence interval (CI). Among European populations, genetically-predicted NAFLD, cALT, cirrhosis (five cohorts), and cirrhosis (FinnGen) were positively associated with liver cancer, with ORs (95% CIs) of 6.62 (3.81-11.50) (p < .001), 2.59 (1.70-3.94) (p < .001), 3.38 (2.41-4.75) (p < .001), and 2.62 (1.20-5.72) (p = .015). Among East Asian populations, there was also a positive association between genetically-predicted cirrhosis and hepatocellular carcinoma (OR = 2.12; 95% CI = 1.78-2.52; p < .001).Conclusion :This study utilized MR to complementarily confirm the positive connections of NAFLD and cirrhosis with liver cancer, as identified in earlier observational research. Subsequent MR investigations involving more liver cancer cases are needed.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Identifying potential drug targets for non-alcoholic fatty liver disease: a drug target Mendelian randomization study
    Hukerikar, N.
    Hingorani, A. D.
    Asselbergs, F. W.
    Finan, C.
    Schmidt, A. F.
    CARDIOVASCULAR RESEARCH, 2024, 120
  • [32] Non-alcoholic fatty liver disease and complications in type 1 and type 2 diabetes: A Mendelian randomization study
    Liu, Ningyuan
    Wang, Ge
    Liu, Chao
    Liu, Jiayi
    Huang, Shengyuan
    Zhou, Yong
    Xiao, Enhua
    DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 365 - 376
  • [33] Causal effect of waist-to-hip ratio on non-alcoholic fatty liver disease: a mendelian randomization study
    Wu, Shihao
    He, Yuhong
    Li, Jiaxing
    Wang, Sijie
    FRONTIERS IN GENETICS, 2024, 15
  • [34] THE EVOLUTION OF DNA METHYLATION CHANGES IN NON-ALCOHOLIC FATTY LIVER DISEASE TO CIRRHOSIS AND LIVER CANCER
    Hlady, Ryan
    Rustgi, Vinod K.
    Robertson, Keith
    Liu, Chen
    GASTROENTEROLOGY, 2018, 154 (06) : S1160 - S1160
  • [35] Non-alcoholic fatty liver disease: from steatosis to cirrhosis
    Leclercq, Isabelle
    Sempoux, Christine
    ACTA ENDOSCOPICA, 2006, 36 (03) : 299 - 314
  • [36] Mendelian Randomization Analysis Identifies Blood Tyrosine Levels as a Biomarker of Non-Alcoholic Fatty Liver Disease
    Gobeil, Emilie
    Maltais-Payette, Ina
    Taba, Nele
    Briere, Francis
    Ghodsian, Nooshin
    Abner, Erik
    Bourgault, Jerome
    Gagnon, Eloi
    Manikpurage, Hasanga D.
    Couture, Christian
    Mitchell, Patricia L.
    Mathieu, Patrick
    Julien, Francois
    Corbeil, Jacques
    Vohl, Marie-Claude
    Theriault, Sebastien
    Esko, Tonu
    Tchernof, Andre
    Arsenault, Benoit J.
    METABOLITES, 2022, 12 (05)
  • [37] Mendelian Randomization Rules Out Causation Between Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease
    Chen, Lanlan
    Fan, Zhongqi
    Sun, Xiaodong
    Qiu, Wei
    Chen, Yuguo
    Zhou, Jianpeng
    Lv, Guoyue
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [38] Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians
    Yeung, Shiu Lun Au
    Borges, Maria Carolina
    Wong, Tommy Hon Ting
    Lawlor, Deborah A.
    Schooling, C. Mary
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2023, 52 (03) : 921 - 931
  • [39] Non-alcoholic fatty liver disease guidelines: An Asian perspective
    Ishii, Hiromasa
    Kajihara, Mikio
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (06) : 769 - 770
  • [40] Evaluation of comorbidity in patients with alcoholic cirrhosis of the liver associated with non-alcoholic fatty liver disease
    Matkovska, N. R.
    Virstiuk, N. H.
    Balan, U., V
    ZAPOROZHYE MEDICAL JOURNAL, 2020, 22 (02) : 166 - 173